CA2146707A1 - N-heteroaroylguanidines substituees comme inhibiteurs de l'echange na+/h+ - Google Patents

N-heteroaroylguanidines substituees comme inhibiteurs de l'echange na+/h+

Info

Publication number
CA2146707A1
CA2146707A1 CA002146707A CA2146707A CA2146707A1 CA 2146707 A1 CA2146707 A1 CA 2146707A1 CA 002146707 A CA002146707 A CA 002146707A CA 2146707 A CA2146707 A CA 2146707A CA 2146707 A1 CA2146707 A1 CA 2146707A1
Authority
CA
Canada
Prior art keywords
compounds
pharmaceuticals
treatment
formula
organs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002146707A
Other languages
English (en)
Other versions
CA2146707C (fr
Inventor
Heinz-Werner Kleemann
Hans-Jochen Lang
Jan-Robert Schwark
Andreas Weichert
Wolfgang Scholz
Udo Albus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2146707A1 publication Critical patent/CA2146707A1/fr
Application granted granted Critical
Publication of CA2146707C publication Critical patent/CA2146707C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CA002146707A 1994-04-11 1995-04-10 N-heteroaroylguanidines substituees comme inhibiteurs de l'echange na+/h+ Expired - Fee Related CA2146707C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4412334.5 1994-04-11
DE4412334A DE4412334A1 (de) 1994-04-11 1994-04-11 Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (2)

Publication Number Publication Date
CA2146707A1 true CA2146707A1 (fr) 1995-10-12
CA2146707C CA2146707C (fr) 2008-10-21

Family

ID=6515052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002146707A Expired - Fee Related CA2146707C (fr) 1994-04-11 1995-04-10 N-heteroaroylguanidines substituees comme inhibiteurs de l'echange na+/h+

Country Status (16)

Country Link
US (1) US5698581A (fr)
EP (1) EP0676395B1 (fr)
JP (1) JP4171078B2 (fr)
CN (1) CN1073988C (fr)
AT (1) ATE248817T1 (fr)
AU (1) AU683722B2 (fr)
CA (1) CA2146707C (fr)
DE (2) DE4412334A1 (fr)
ES (1) ES2206471T3 (fr)
FI (1) FI951681A (fr)
HU (1) HUT71616A (fr)
IL (1) IL113310A (fr)
NO (1) NO304426B1 (fr)
NZ (1) NZ270894A (fr)
TW (1) TW349941B (fr)
ZA (1) ZA952930B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994396A (en) * 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8242147B2 (en) 2002-02-11 2012-08-14 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
CA2195697A1 (fr) * 1996-02-02 1997-08-03 Masahumi Kitano Derives substitues de la guanidine, procede pour leur obtention et leurs utilisations pharmaceutiques
DE19605610A1 (de) * 1996-02-15 1997-08-21 Hoechst Ag Substituierte Thiophenylalkenylcarbonsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6136984A (en) * 1996-04-22 2000-10-24 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted thiophenes and of arrays of substituted thiophenes
JPH09291076A (ja) * 1996-04-24 1997-11-11 Sumitomo Pharmaceut Co Ltd 置換グアニジン誘導体およびその製法
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ES2237080T3 (es) 1998-02-27 2005-07-16 Pfizer Products Inc. Derivados de n-((anillo di- o triaza dinsaturado de cinco miembros sustituido)carbonil)guanidina para el tratamiento de isquemia.
ME00275B (fr) 1999-01-13 2011-02-10 Bayer Corp DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
WO2000042012A1 (fr) 1999-01-13 2000-07-20 Bayer Corporation DIPHENYLUREES A SUBSTITUANTS φ-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003068229A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
FR2842524B1 (fr) * 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
US7196207B2 (en) * 2002-07-24 2007-03-27 Mitsui Chemicals, Inc. Method for producing 2-alkyl-3-aminothiophene derivative
DE60329030D1 (de) 2002-12-04 2009-10-08 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR20070011475A (ko) * 2004-05-12 2007-01-24 쉐링 코포레이션 Ｃｘｃｒ1 및 ｃｘｃｒ2 케모카인 길항제
DE102006027229A1 (de) * 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
WO2008054605A2 (fr) * 2006-10-06 2008-05-08 Merck & Co., Inc. Inhibiteurs de transcriptase inverse non nucléosidique
KR101722289B1 (ko) 2009-07-08 2017-03-31 데르미라 (캐나다), 인코포레이티드 피부과 질환 또는 증상의 치료에 유용한 ｔｏｆａ 유사체
EP2602248A1 (fr) 2011-12-05 2013-06-12 University Of Leicester Nouveaux composés pyrroliques
RU2631011C1 (ru) * 2016-07-12 2017-09-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный технический университет" Устройство для получения направленной силы инерции

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053674B (it) * 1968-01-31 1981-10-10 Istituto Farmacobiologico Sero N amidino carbossiamidi ossazoliche ad azione natriuretica
FR2027285A1 (en) * 1968-12-29 1970-09-25 Dainippon Pharmaceutical Co Pharmaceutical derivs of 4-nitropyrrol-2- - carboxylic acid amides
BE758762A (fr) * 1969-11-12 1971-04-16 Shionogi & Cy Ltd Derives de l'isoxazole et leur preparation
FR2073284B1 (fr) * 1969-12-23 1973-07-13 Ferlux
SU380651A1 (ru) * 1971-05-11 1973-05-15 вители Саратовский государственный университет имени Н. Г. Чернышевского , Саратовский государственный медицинский институт Способ получения гуанидидов фуранкарбоновых или тетрагидрофуранкарбоновых кислот
US4894376A (en) * 1988-02-26 1990-01-16 Trustees Of The University Of Pennsylvania Methods of treating diseases characterized by hyperexcitability of neurons
US5002965A (en) * 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
TW213903B (fr) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
ES2089600T3 (es) * 1992-02-15 1996-10-01 Hoechst Ag Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas.
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
DE59307360D1 (de) * 1992-02-15 1997-10-23 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE59304166D1 (de) * 1992-07-01 1996-11-21 Hoechst Ag 3,4,5-Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE59305042D1 (de) * 1992-09-22 1997-02-20 Hoechst Ag Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
PT590455E (pt) * 1992-09-28 2001-04-30 Hoechst Ag 1(2h)-isoquinolinas substituidas anti-arritmicas e cardioprotectoras processo para a sua preparacao medicamento contendo estes compostos e sua utilizacao para a preparacao de um medicamento para o combate de falhas cardiacas
US5260091A (en) * 1992-10-21 1993-11-09 Interneuron Pharmaceuticals Inc. Salt taste enhancers
EP0603650B1 (fr) * 1992-12-16 1997-04-02 Hoechst Aktiengesellschaft Aminobenzoylguanidines 3,5, substituées, procédé de leur préparation, leur application à titre de médicament ou d'agent diagnostique ainisi que un médicament les contenant
CA2121391A1 (fr) * 1993-04-28 1994-10-29 Atsuyuki Kojima Derives d'indoloylguanidine
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
DE4327244A1 (de) * 1993-08-13 1995-02-16 Hoechst Ag Harnstoffsubstituierte Benzoylguandine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4344550A1 (de) * 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
TW415937B (en) * 1994-01-25 2000-12-21 Hoechst Ag Phenyl-substituted alkylcarboxylic acid guanidides bearing perfluoroalkyl groups, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US5994396A (en) * 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8841330B2 (en) 1999-01-13 2014-09-23 Bayer Healthcare Llc Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8242147B2 (en) 2002-02-11 2012-08-14 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US8618141B2 (en) 2002-02-11 2013-12-31 Bayer Healthcare Llc Aryl ureas with angiogenesis inhibiting activity
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR

Also Published As

Publication number Publication date
NZ270894A (en) 1997-09-22
DE59510782D1 (de) 2003-10-09
US5698581A (en) 1997-12-16
ES2206471T3 (es) 2004-05-16
NO951405L (no) 1995-10-12
EP0676395B1 (fr) 2003-09-03
IL113310A0 (en) 1995-07-31
NO951405D0 (no) 1995-04-10
CN1073988C (zh) 2001-10-31
JP4171078B2 (ja) 2008-10-22
EP0676395A3 (fr) 1996-03-06
FI951681A (fi) 1995-10-12
IL113310A (en) 2000-06-29
DE4412334A1 (de) 1995-10-19
AU683722B2 (en) 1997-11-20
TW349941B (en) 1999-01-11
HU9501035D0 (en) 1995-06-28
ATE248817T1 (de) 2003-09-15
NO304426B1 (no) 1998-12-14
FI951681A0 (fi) 1995-04-07
AU1635495A (en) 1995-10-19
HUT71616A (en) 1996-01-29
ZA952930B (en) 1996-01-26
CN1117044A (zh) 1996-02-21
JPH07291927A (ja) 1995-11-07
CA2146707C (fr) 2008-10-21
EP0676395A2 (fr) 1995-10-11

Similar Documents

Publication Publication Date Title
CA2146707A1 (fr) N-heteroaroylguanidines substituees comme inhibiteurs de l'echange na+/h+
CA2130944A1 (fr) Derives de substitution en ortho de benzoylguanidines; methode de preparation; utilisation en pharmacie ou en diagnostic; produit pharmaceutique a base de ces derives
US4810777A (en) Antimicrobial compounds
CA2213714A1 (fr) Guanidides alkenylcarboxyliques substitues par un phenyle , procede de preparation, utilisation comme medicament ou produit diagnostique et medicament contenant ces composes
CA2116165A1 (fr) Benzenesulfonylurees et -thiourees substituees - procedes pour leur preparation et leur utilisation comme produits pharmaceutiques
CA2089439A1 (fr) Benzoylguanidines a substituant en 3,5, procede d'obtention et emploi comme medicament ou diagnostique, et medicament qui les contient
CA2089440A1 (fr) Benzoylguanidines a substitution en position ortho, procede d'obtention, emploi comme medicament ou outil diagnostique et medicaments qui les contiennent
EA200000409A1 (ru) Соединение, фармацевтическая композиция, способ ингибирования гибели клетки в одной клетке или ткани, способ лечения или снижения клеточной смерти, способ лечения или профилактики поликистозного заболевания почек или анемии/эритропоэза у животных, способ защиты органа или ткани млекопитающего от гибели клеток, способ снижения или профилактики гибели клеток в органе или ткани донора после их трансплантации, способ снижения или предотвращения гибели спермы или яйцеклеток
CA2546602A1 (fr) Guanidines monoacylees
MY121708A (en) Five- membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic and medicament comprising them
CA2111386A1 (fr) Benzoylguanidines substituees, mode de preparation, utilisation comme medicament ou a des fins diagnostiques, et medicament en contenant
CA2136824A1 (fr) Composes phosponocarboxylate pour le traitement du metabolisme anormal du calcium et du phosphate
CA2111512A1 (fr) Aminobenzoylguanidines a substituant en 3,5, procede d'obtention, emploi comme medicament ou outil de diagnostic, et medicament qui les contient
CA2206366A1 (fr) 2-naphthoylguanidines de substitution, processus de preparation de celles-ci, leur utilisation comme medicament ou a des fins diagnostiques et medicament les renfermant
CA2220533A1 (fr) 3-amidochromanylsulfonyl(thio)urees, procedes pour leur preparation, leur utilisation et preparations pharmaceutiques contenant ces composes
AU678866B2 (en) Amino-substituted benzenesulfonylureas and -thioureas, processes for their preparation, and their use as pharmaceuticals
TW429243B (en) Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them
MY117304A (en) Ortho-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic, agent and a medicament comprising them.
US6156800A (en) 4-fluoroalkyl-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
CA2197628A1 (fr) Guanidides de l'acide thiophenylalkenylcarboxylique substitue, procede pour leur preparation, leur utilisation comme medicament ou produit diagnostique et medicament les contenant
EP0334813A3 (en) Agents for the protection of plants against diseases
CA2206362A1 (fr) 1-naphthoylguanidines de substitution, processus de preparation de celles-ci, leur utilisation comme medicament ou a des fins diagnostiques et medicament les renfermant
NO302750B1 (no) Substituerte benzensulfonylurinstoffer og -tiourinstoffer, og deres anvendelse for fremstilling av legemidler
MY116861A (en) Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them
MY129959A (en) Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140410